Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833169 · ClinicalTrials.gov registry record · Phase 2
BKM120 for Patients With PI3K-activated Tumors
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT01833169 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 146 participants.
The verdict
NCT01833169, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Interventions
- DRUG BKM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2013-03-29 |
| Est. Completion | 2016-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833169
The ClinicalTrials.gov registry entry for NCT01833169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKM120 is the first listed.
NCT01833169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833169 about?
NCT01833169 is a clinical study titled "BKM120 for Patients With PI3K-activated Tumors". The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
What is the current status of trial NCT01833169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2013-03-29. Estimated completion is 2016-09-26.
What interventions are being tested in trial NCT01833169?
The interventions under investigation include: BKM120 (DRUG).
Who is sponsoring clinical trial NCT01833169?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.